Organigram to Acquire Aurora Cannabis for C$561 Million, Outbidding Curaleaf’s Hostile Offer

The BAT-backed transaction offers Aurora shareholders a 21% premium over Curaleaf’s bid and would create a global cannabis company with more than C$623 million in annual revenue.

Organigram Global Inc. (NASDAQ: OGI; TSX: OGI) has agreed to acquire Aurora Cannabis Inc. (NASDAQ: ACB; TSX: ACB) in a transaction valued at approximately C$561 million, dealing a major blow to Curaleaf Holdings Inc. (TSX: CURA; OTCQX: CURLF) and its hostile takeover campaign.

The agreement, announced Tuesday, November 3, values Aurora at C$7.80 per share, representing a 93% premium to its unaffected August 10 closing price and a 21% premium to the implied value of Curaleaf’s competing offer as of November 2.

Both companies’ boards unanimously approved the transaction, which is supported by a C$187.5 million investment from British American Tobacco (NYSE: BTI), a major strategic shareholder in Organigram.

The proposed combination would create one of the largest internationally diversified cannabis companies, bringing together Organigram’s Canadian recreational cannabis operations and European expansion strategy with Aurora’s established international medical cannabis business.

Organigram Wins Aurora’s Board Support

The announcement follows nearly three months of takeover activity involving Aurora and Curaleaf.

Curaleaf disclosed its intention to pursue Aurora in August and subsequently revised its hostile offer on October 6. Aurora’s board rejected the proposal, arguing that it undervalued the company.

Organigram’s competing agreement now offers Aurora shareholders three alternatives: C$7.80 in cash, 5.8626 Organigram shares, or a combination of C$3.75 in cash and 3.0431 Organigram shares for each Aurora share. Elections are subject to aggregate cash and share limits and proration.

Aurora shareholders would own approximately 35% of the combined company’s fully diluted economic equity and hold approximately 42% of its voting rights.

“This Transaction is a defining step in Organigram’s strategy to build a disciplined, global cannabis leader,” said James Yamanaka, CEO of Organigram.

Aurora Executive Chairman and CEO Miguel Martin said the combination would accelerate the company’s international growth strategy by strengthening commercial execution, expanding product development capabilities and extending its global operating network.

Aurora’s board is recommending that shareholders approve the Organigram transaction and reject Curaleaf’s outstanding hostile bid.

Although the announcement significantly strengthens Organigram’s position, the acquisition has not yet closed, and Curaleaf’s offer remains an outstanding competing proposal.

British American Tobacco Backs the Acquisition

The transaction also underscores the growing role of established multinational consumer goods companies in financing cannabis industry consolidation.

British American Tobacco, through its investment subsidiary BT DE Investments, has agreed to invest £100 million, equivalent to approximately C$187.5 million, in Organigram through a concurrent private placement.

The investment will help finance the cash component of the acquisition and related transaction expenses.

Organigram has also secured commitments from ATB Financial for senior secured credit facilities totaling up to C$210 million.

BAT has entered into a voting agreement supporting the acquisition and opposing competing proposals. Its participation provides Organigram with financing support and an influential strategic shareholder as the company expands internationally.

The transaction illustrates an important competitive distinction in the cannabis industry: companies with access to established institutional investors and financing partners may be better positioned to pursue acquisitions than competitors facing more restrictive capital markets.

A Combined Company With C$623 Million in Annual Revenue

The proposed merger would create a cannabis business with approximately C$623.2 million in combined pro forma net revenue for the twelve months ended June 30, 2026.

During that period, the two companies generated approximately C$80 million in combined adjusted EBITDA and C$254.4 million in gross profit before fair value adjustments.

Medical cannabis accounted for approximately 60% of combined revenue, with consumer cannabis representing the remaining 40%.

That revenue composition is particularly significant.

While Canadian recreational cannabis continues to face price competition and market saturation, international medical cannabis has become an increasingly important source of growth for Canadian producers.

Aurora has developed medical cannabis operations and distribution networks across Canada, Germany, Australia and New Zealand.

Organigram brings established Canadian recreational brands, cultivation and manufacturing operations, research capabilities and a growing European commercial presence following its acquisition of Sanity Group.

Together, the companies would operate five EU-GMP-certified production and distribution facilities, strengthening their ability to supply regulated medical markets.

More Than C$50 Million in Expected Synergies

Organigram and Aurora have identified more than C$50 million in potential synergies through procurement efficiencies, distribution consolidation, cross-selling opportunities, and production optimization.

The combined business would also be able to direct international demand toward lower-cost production facilities across its network.

However, the projected savings remain subject to execution.

Integrating cultivation facilities, manufacturing operations, distribution networks, and commercial teams across multiple jurisdictions introduces operational and regulatory complexity.

The companies will also need to demonstrate that greater scale can improve profitability rather than simply increase their exposure to competitive international markets.

What Happens Next for Curaleaf?

The agreement creates a significant challenge for Curaleaf, which had pursued Aurora as part of its international expansion strategy.

Aurora’s established medical cannabis infrastructure, particularly its European manufacturing capabilities and commercial relationships, would have strengthened Curaleaf’s position outside the United States.

Organigram’s competing offer now places those assets within reach of another Canadian operator backed by British American Tobacco.

Curaleaf could reconsider its strategy or seek to improve its offer, although no further counterproposal has been announced.

The Organigram-Aurora transaction remains subject to shareholder, court, and regulatory approvals.

Shareholder meetings are expected in December 2026, with the companies targeting completion in January 2027.

For the broader cannabis industry, the takeover battle demonstrates the increasing strategic value of internationally certified production facilities, established medical distribution networks and access to acquisition financing.

It also raises a larger question for cannabis investors: whether consolidation can deliver sustainable profitability in an industry where regulatory complexity, price competition and financing constraints continue to shape corporate strategy.

Organigram has secured the support of Aurora’s board. Turning that agreement into a successful international cannabis business will be the next challenge.

How the Curaleaf–Aurora Takeover Battle Unfolded

The Organigram agreement marks the latest chapter in a takeover battle IgniteIt has followed since August, when Curaleaf first publicly pursued Aurora with a hostile acquisition proposal.

The dispute began with Aurora challenging Curaleaf’s account of their negotiations, including disagreements over when financial terms were presented and whether Aurora had refused to engage. Aurora subsequently urged shareholders to take no action while its independent special committee evaluated the offer.

Curaleaf Chairman and CEO Boris Jordan outlined the strategic rationale in an exclusive IgniteIt interview, arguing that Curaleaf could improve the productivity of Aurora’s cultivation facilities and generate substantial operating synergies.

But the financial case was far from settled. In an analysis for IgniteIt, economist Rolando García examined why the market doubted the transaction, highlighting the gap between Curaleaf’s offer and Aurora’s trading price, the challenges of securing shareholder approval and the possibility of an alternative bidder.

The confrontation intensified in October. Curaleaf increased its offer by 25%, from $4 to $5 per share, but Aurora continued to reject the proposal. Curaleaf then accused Aurora of denying it due diligence access while potentially engaging Organigram and British American Tobacco.

The dispute also reached securities regulators. Curaleaf challenged Aurora’s at-the-market share issuance program before the Alberta Securities Commission, alleging that the sales diluted shareholders and complicated its takeover attempt. The regulator dismissed the application, prompting another public confrontation between Curaleaf and Aurora on October 27.

The Organigram–Aurora deal underscores how consolidation, access to capital and international expansion are reshaping the cannabis industry. These developments, alongside the evolving federal regulatory landscape and shifting investor priorities, will be central to the conversations at IgniteIt’s Cannabis Capital & Policy Summit in Washington, D.C. on November 18. Join industry executives, investors, and policymakers to examine the forces driving the next phase of cannabis investment, regulation, and corporate strategy.